Anteris Technologies Global Corp. reported full-year 2025 results and provided a corporate update. Net operating cash outflows for the year ended Dec. 31, 2025 were $77.8 million, which the company said was in line with increased clinical, regulatory and manufacturing requirements to support the PARADIGM Trial. R&D expenses totaled $69.1 million and selling, general and administrative expenses were $26.1 million. The company said it initiated the global pivotal PARADIGM Trial and received FDA Investigational Device Exemption approval in the fourth quarter of 2025 to begin the trial in the United States. It reported 30-day outcomes from 100 patients and 1-year outcomes from 65 patients treated with the DurAVR THV in rolling cohorts of small annuli, symptomatic severe aortic stenosis patients, and completed the first double DurAVR implant for valve-in-valve replacement in both the mitral and aortic positions. Anteris also reported ISO 13485 certification for DurAVR THV production and said it completed aggregate capital raises totaling $320 million in early 2026, including a strategic investment from Medtronic.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.